Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes

Diabetic Medicine

Volumn 24, Issue 5, 2007, Pages 541-549

  Betteridge, D J ^a   Gibson, J M ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

Atorvastatin; Lipids; Low density lipoprotein cholesterol; Rosuvastatin; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN; ATORVASTATIN; CREATININE; HEMOGLOBIN A1C; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES;

EID: 34247617826     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02095.x     Document Type: Article

References (33)

1. de Grauw WJ, van de Lisdonk EH, van den Hoogen HJ, van Weel C. Cardiovascular morbidity and mortality in type 2 diabetic patients: a 22-year historical cohort study in Dutch general practice. Diabet Med 1995 12 : 117 122.
2. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 2000 23 : 40 44.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
4. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörä lä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993 36 : 1175 1184.
5. Department of Health. National Service Framework for Diabetes. London : Department of Health, 2001.
6. Haffner SM. Statin therapy for the treatment of diabetic dyslipidemia. Diabetes Metab Res Rev 2003 19 : 280 287.
7. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003 115 : 24S 28S.
8. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988 29 : 1461 1473.
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986 232 : 34 47.
10. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003 361 : 777 780.
11. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001 358 : 2026 2033.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 5 36 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
13. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 : 2005 2016.
14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003 24 : 1601 1610.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001 285 : 2486 2497.
17. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 : 227 239.
18. Pyörälä K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys. Diabetologia 2004 47 : 1257 1265.
19. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998 81 : 582 587.
20. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003 92 : 152 160.
21. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003 91 : 3C 10C.
22. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004 147 : 705 713.
23. WHO. Definition Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation, Part I: Diagnosis and Classification of Diabetes Mellitus. Geneva : World Health Organization, 1999.
24. British Cardiac Society, British Hypertension Society; Diabetes UK, HEART UK, Primary Care Cardiovascular Society; Stroke Association. JBS 2 : Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 91 : v1 v52.
25. Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY) II. Am Heart J 2006 151 975e1 975e9.
26. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,0 56 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
27. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 : 937 952.
28. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apoC3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 2000 43 : 703 708.
29. Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004 6 : 359 365.
30. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogenous assays. Clin Chem 2001 47 : 1579 1596.
31. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003 92 : 670 676.
32. Shepherd J, Hunninghake DB, Stein EA, Kastelein JJP, Harris S, Pears J et al. Safety of rosuvastatin. Am J Cardiol 2004 94 : 882 888.
33. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep 2002 4 : 34 41.